Recombinant Human IRAK4 protein, His-tagged

• Cat.No.: IRAK4-7074H
• Product Overview: Recombinant Human IRAK4 aa. (Gly189~Glu427) fused with N-terminal His tag was produced in E. coli cells.

Specification

• Source: E. coli
• Species: Human
• Tag: His
• Form: Freeze-dried powder
• Molecular Mass: 31kDa as determined by SDS-PAGE reducing conditions.
• Protein length: Gly189~Glu427
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Purity: >92%
• Characteristic: The isoelectric point is 5.1.
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
• Stability: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Concentration: 200ug/mL
• Storage buffer: 10mM PBS, pH7.4, containing 1mM DTT, 5% trehalose, 0.01% sarcosyl and Proclin300
• Reconstitution: Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex

Gene Information

• Gene Name: IRAK4 interleukin 1 receptor associated kinase 4 [ Homo sapiens (human) ]
• Official Symbol: IRAK4
• Synonyms: IRAK4; interleukin 1 receptor associated kinase 4; IPD1; REN64; IRAK-4; NY-REN-64; interleukin-1 receptor-associated kinase 4; renal carcinoma antigen NY-REN-64
• Gene ID: 51135
• mRNA Refseq: NM_001114182.2
• Protein Refseq: NP_001107654.1
• UniProt ID: Q9NWZ3

Reviews

11/16/2021

Its potency and specificity make it a valuable tool for studying specific biological pathways or mechanisms.

03/01/2020

Their technical expertise and experience in the field allow them to provide invaluable guidance and assistance.

07/16/2018

They can offer insights on experimental design, optimal usage protocols, and troubleshoot any challenges that may arise during the course of the trial.

Q&As

What conditions are associated with IRAK4 dysregulation?

Rheumatoid arthritis, lupus, inflammatory bowel diseases, and certain cancers may involve IRAK4.

Are there any ongoing clinical trials involving IRAK4 inhibitors?

Yes, several trials are investigating IRAK4 inhibitors' effectiveness and safety in various diseases.

What are the methods used to target IRAK4 in treatment?

Small molecule inhibitors and monoclonal antibodies are primary methods for modulating IRAK4 activity.

How does the expression of IRAK4 differ in healthy individuals and those with autoimmune diseases?

Individuals with autoimmune diseases often show increased IRAK4 expression compared to healthy individuals.

How does IRAK4 inhibition impact the immune response?

By blocking IRAK4, the overactive immune response in certain diseases can be suppressed.